TESAMORELIN



NAME OF DRUG : TESAMORELIN

ALSO KNOWN AS : EGRIFTA

LABORATORY : Theratechnologies

STATUS AND ADVANCEMENT

Type of drug : growth hormone releasing hormone (GHRH) analogue

Clinical trials advancement : Ongoing Phase 2a

Estimated time to market : 96 months.

LABORATORY ABSTRACT ON THE DRUG

Tesamorelin is a growth hormone releasing hormone (GHRH) analogue that increases endogenous growth hormone secretion. Tesamorelin is FDA-approved for the reduction of visceral fat in HIV-infected individuals. In a previous study, treatment with tesamorelin in HIV-infected individuals selected for abdominal adiposity reduced liver fat. The current study is designed to test the effect of tesamorelin on liver fat and steatohepatitis in HIV-infected individuals who have NAFLD. The investigators hypothesize that tesamorelin will reduce liver fat and will also ameliorate the inflammation, fibrosis, and hepatocellular damage seen in conjunction with NASH.

RECENT NEWS ON TESAMORELIN

2019-04-01 : STUDY CONFIRMS TESAMORELIN SIGNIFICANTLY REDUCES LIVER FAT IN HIV PATIENTS WITH NAFLD

SOME PUBLICATIONS RELATED WITH TESAMORELIN

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH TESAMORELIN


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE